Novo, the Danish pharmaceutical company known for Ozempic, announced a partnership with Anthropic on Wednesday to apply Claude and Claude Science to drug discovery research. The company will use Anthropic's models to accelerate scientific reasoning across its R&D organization.
"AI's increasing capability brings with it the potential to compress a century's worth of biological and medical breakthroughs into a decade," said Anthropic co-founder and CEO Dario Amodei in the announcement. Novo president and CEO Mike Doustdar described the partnership as a way to "supercharge" the company's research and development efforts on chronic disease treatments.
The deal follows Novo's existing work with OpenAI. In April, the company adopted GPT-Rosalind, OpenAI's science-focused model, to analyze complex datasets, identify candidate drugs, and shorten the gap between lab research and patient access. Novo now runs AI tools from two competing frontier model providers.
Novo has been building infrastructure to support this push since 2024, when the Novo Nordisk Foundation partnered with Nvidia and the Export and Investment Fund of Denmark (EIFO) to create the Danish Centre for AI Innovation. That centre operates Gefion, Denmark's first AI-ready supercomputer.
Anthropic has been expanding its life sciences partnerships. In May 2026, the company announced a collaboration with Bristol Myers Squibb to deploy Claude across research, clinical development, manufacturing, commercial, and corporate functions.
The Novo partnership reflects a broader trend in pharma. Drugmakers are increasingly integrating AI across research and development to accelerate new drug discovery, with multiple large pharmaceutical firms now running programs with competing AI companies in parallel.